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Abstract
IMPORTANCE—The ability to predict the pathology underlying different neurodegenerative 
syndromes is of critical importance owing to the advent of molecule-specific therapies.
OBJECTIVE—To determine the rates of positron emission tomography (PET) amyloid positivity 
in the main clinical variants of primary progressive aphasia (PPA).
DESIGN, SETTING, AND PARTICIPANTS—This prospective clinical-pathologic case series 
was conducted at a tertiary research clinic specialized in cognitive disorders. Patients were 
evaluated as part of a prospective, longitudinal research study between January 2002 and 
December 2015. Inclusion criteria included clinical diagnosis of PPA; availability of complete 
speech, language, and cognitive testing; magnetic resonance imaging performed within 6 months 
of the cognitive evaluation; and PET carbon 11–labeled Pittsburgh Compound-B or florbetapir F 
18 brain scan results. Of 109 patients referred for evaluation of language symptoms who 
underwent amyloid brain imaging, 3 were excluded because of incomplete language evaluations, 5 
for absence of significant aphasia, and 12 for presenting with significant initial symptoms outside 
of the language domain, leaving a cohort of 89 patients with PPA.
MAIN OUTCOMES AND MEASURES—Clinical, cognitive, neuroimaging, and pathology 
results.
RESULTS—Twenty-eight cases were classified as imaging-supported semantic variant PPA (11 
women [39.3%]; mean [SD] age, 64 [7] years), 31 nonfluent/agrammatic variant PPA (22 women 
[71.0%]; mean [SD] age, 68 [7] years), 26 logopenic variant PPA (17 women [65.4%]; mean [SD] 
age, 63 [8] years), and 4 mixed PPA cases. Twenty-four of 28 patients with semantic variant PPA 
(86%) and 28 of 31 patients with nonfluent/agrammatic variant PPA (90%) had negative amyloid 
PET scan results, while 25 of 26 patients with logopenic variant PPA (96%) and 3 of 4 mixed PPA 
cases (75%) had positive scan results. The amyloid positive semantic variant PPA and nonfluent/
agrammatic variant PPA cases with available autopsy data (2 of 4 and 2 of 3, respectively) all had 
a primary frontotemporal lobar degeneration and secondary Alzheimer disease pathologic 
diagnoses, whereas autopsy of 2 patients with amyloid PET–positive logopenic variant PPA 
confirmed Alzheimer disease. One mixed PPA patient with a negative amyloid PET scan had Pick 
disease at autopsy.
CONCLUSIONS AND RELEVANCE—Primary progressive aphasia variant diagnosis 
according to the current classification scheme is associated with Alzheimer disease biomarker 
status, with the logopenic variant being associated with carbon 11–labeled Pittsburgh Compound-
B positivity in more than 95% of cases. Furthermore, in the presence of a clinical syndrome highly 
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predictive of frontotemporal lobar degeneration pathology, biomarker positivity for Alzheimer 
disease may be associated more with mixed pathology rather than primary Alzheimer disease.
Primary progressive aphasia (PPA) is a clinically and pathologically heterogeneous 
condition in which language impairment is the predominant cause of functional impairment 
during the initial phases of disease.1 In 2011, an international consortium of investigators 
established a classification scheme for the 3 most common variants: the semantic (svPPA), 
nonfluent/agrammatic (nfvPPA), and logopenic (lvPPA) variants of PPA.2 Classification 
may occur at 1 of 3 levels: clinical, imaging-supported, or definite pathologic diagnosis. 
These guidelines reflected the accumulated knowledge of the patterns of speech and 
language dysfunction, brain atrophy, and underlying pathology typically associated with 
each clinical variant and represent a collective effort to increase comparability between 
studies and eventually improve the ability to predict the underlying pathology.
The ability to detect fibrillar amyloid-β plaque depositions using carbon 11–labeled 
Pittsburgh Compound-B (11C-PIB)3 or fluorinated amyloid positron emission tomography 
(PET) tracers4 allows in-vivo identification of cases due to putative Alzheimer disease. A 
few studies have reported amyloid imaging and pathologic results in PPA.5–8 Taken together, 
these reports suggest that svPPA and nfvPPA are generally caused by frontotemporal lobar 
degeneration (FTLD),9 mainly tau (including Pick disease, corticobasal degeneration, 
progressive supranuclear palsy) and TAR-DNA binding protein 43 (TDP-43) 
proteinopathies, while lvPPA is mostly caused by Alzheimer disease. However, the 
prevalence of FTLD and Alzheimer disease pathologic findings or biomarkers in each 
variant has been inconsistent across the literature (svPPA, 0%–16% Alzheimer disease; 
nfvPPA, 13%–31%; lvPPA, 54%–92%).5–8,10–14 This may be caused by the fact that most of 
these studies are retrospective and may not have had adequate records or appropriate test 
batteries to apply the current criteria. Therefore, prospective validation with biomarker and 
autopsy data remains scarce and highly necessary.
We studied amyloid brain imaging in a large cohort of patients with prospectively diagnosed 
PPA to test the hypothesis that classification according to the current criteria in well-
characterized patients with language and magnetic resonance imaging (MRI) evaluations 
will result in groups with largely homogeneous biomarker features. A second objective was 
to analyze amyloid “discordant” (amyloid positive svPPA and nfvPPA and amyloid negative 
lvPPA) and mixed cases (PPAm) in search of characteristics that may aid in their 
identification.
Methods
Participant Selection and Characterization
We recruited participants that presented prospectively to the University of California San 
Francisco (UCSF) Memory and Aging Center between January 2002 and December 2015 as 
part of an ongoing PPA research project. We included patients that met the following 
criteria: clinical diagnosis of PPA; availability of complete speech, language, and cognitive 
test results; MRI performed within 6 months of the cognitive evaluation; and PET 11C-PiB 
or florbetapir F 18 brain scan results. As part of the research evaluation, all participants 
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underwent a history and physical examination by a neurologist, a structured caregiver 
interview by a nurse, a battery of neuropsychological tests, multimodal brain imaging scans, 
as well as an extensive battery of language tests. After initial evaluation, a syndromic 
diagnosis was reached by consensus between the multidisciplinary evaluation team. Initial 
diagnosis was based on clinical judgment after considering all available neurologic, 
cognitive, language, and structural MRI data. Amyloid imaging results were not available 
for any participant at the time of initial diagnosis. Since 2002, the UCSF Memory and Aging 
Center PPA research project has classified patients with PPA into svPPA, nfvPPA, and 
lvPPA using the same core clinical evaluation presented in this article. The features used for 
classification have remained largely analogous since they were first described in 200415; 
however, they have been refined and operationalized by senior investigators in the field as 
described in 2008 and 2011.2,16 The tripartite framework of the classification system and the 
nature of the delineated patient groups have not changed during the evolution of the criteria 
(see eAppendix 1 in the Supplement). Furthermore, each case that presented before 2011 
was reviewed retrospectively to determine if their diagnosis would change with application 
of current criteria, and none warranted change. We report the prospective PPA clinical 
variant diagnoses made by consensus at presentation between 2002 and 2015. When it was 
not possible to identify a predominant area of language impairment or more than 1 area was 
impaired (eg, motor speech, repetition difficulties), a diagnosis of PPAm was made.
One hundred and nine patients were referred to the UCSF Memory and Aging Center for 
evaluation of language symptoms and underwent amyloid imaging between 2002 and 2015. 
Of these, 3 patients were excluded because of inability to complete the language evaluation 
owing to advanced severity of disease, 5 for absence of significant aphasia, and 12 for 
presenting with significant initial symptoms outside of the language domain and 
consequently not meeting root PPA criteria (eTable in the Supplement). This left a cohort of 
89 patients with PPA (28 svPPA [31.5%], 31 nfvPPA [34.8%], and 26 lvPPA [29.2%] with 4 
PPAm [4.5%]).
We recruited healthy control individuals from the San Francisco Aging Cohort Study 
(matched for age, sex, and scanner type) for the cognitive (n = 10; mean [SD] age, 69 [8] 
years; 7 women [70%]) and MRI (n = 84; mean [SD] age, 64 [8)] years; 50 women [60%]) 
contrasts with patients. All control individuals had a Clinical Dementia Rating Scale Sum of 
Boxes score of 0, a normal neurologic examination, and no cognitive complaints. All 
participants underwent written informed consent and the study was approved by the UCSF, 
University of California Berkeley, and Lawrence Berkeley National Laboratory human 
research committees.
Cognitive Tests
All patients received the UCSF neuropsychological battery17 and UCSF speech and 
language battery (Table 1), which have been described extensively in previous publications.
18,19 Briefly, speech and syntactic production were evaluated using the spontaneous speech 
section from the Western Aphasia Battery and a writing sample, motor speech was evaluated 
using the Motor Speech Evaluation (MSE),20 single word comprehension was evaluated 
with items of the Peabody Picture Vocabulary Test-revised,21 repetition by the Western 
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Aphasia Battery repetition subtest, and syntactic comprehension abilities were tested using 
the Sequential Command subtest of the Western Aphasia Battery and by 1 of 2 experimental 
syntax comprehension tests that systemically vary sentence length and syntactic complexity 
to take into account the effect of verbal working memory load on syntactic comprehension 
(selected subtests of the Curtiss-Yamada Comprehensive Language Evaluation-Receptive22 
or the UCSF Grammar Comprehension Test23). The Curtiss-Yamada Comprehensive 
Language Evaluation-Receptive text was administered until 2010; the score on the 2 latter 
tests are summarized into 1 percentage correct syntax comprehension score in Table 1.
Structural Magnetic Resonance Imaging
All patients and control individuals underwent whole-brain structural MRI using a 1.5T 
(Siemens Healthcare),15,24 3T (Siemens Healthcare),25 or 4T (Bruker Corporation and 
Siemens Healthcare)26 scanner as previously described. We used voxel-based morphometry 
to study gray-matter atrophy patterns of svPPA (n = 24), nfvPPA (n = 28), and lvPPA (n = 
25) groups (only including cases with typical amyloid imaging status) as well as each 
individual case with discordant amyloid imaging status and each PPAm case (eAppendix 2 
in the Supplement).
Positron Emission Tomography
Carbon11–labelled Pittsburgh Compound-B (n = 99) and florbetapir F 18 (n = 10) PET were 
performed at Lawrence Berkeley National Laboratory as previously described.27 Native 
space standardized uptake value ratios (SUVRs) were created for 11C-PIB scans only by 
normalizing mean images (at 50- to 70-minutes postinjection) by mean activity in 
cerebellum gray matter. Visual reads of native space 11C-PIB or florbetapir F 18 SUVR 
images were performed by experienced investigators blinded to clinical data (G.D.R., H.J.R., 
or W.J.J.) using published criteria.28,29 Visual inspection based on these criteria has been 
validated previously as a reproducible and reliable estimate of increased tracer uptake when 
compared with quantitative analysis.28,30
Neuropathology
All brain autopsies were performed by the UCSF Neurodegenerative Disease Brain Bank. 
Pathologic assessments were performed using institution-specific protocols27 and included 
tissue sampling in regions relevant to the differential diagnosis of dementia based on 
published consensus criteria (eAppendix 3 in the Supplement).9,31
Statistical Analysis of Clinical and Cognitive Data
Demographic and cognitive data were compared between PPA variants using 1-way analysis 
of variance followed by post hoc comparisons of continuous variables with Bonferroni 
adjustments. χ2 test was used for dichotomous variables. To identify factors that may help 
identify PPA cases with discordant amyloid imaging within each PPA variant, we converted 
the raw cognitive test scores of amyloid discordant PPA cases into z scores with respect to 
the mean score of the group with typical amyloid imaging status. To highlight the pattern of 
impaired and relatively preserved cognitive functions in patients with PPAm, we calculated z 
scores with respect to the healthy control group.
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Demographic and Genetic Data
Comparison of demographic characteristics (Table 1) between variants revealed significantly 
older age at symptom onset in patients with nfvPPA than patients with svPPA or lvPPA. A 
significantly higher proportion of patients with lvPPA had at least 1 apolipoprotein E ε4 
allele (11 of 26 [44%]) compared with patients with nfvPPA (3 of 31 [11%]). No mutations 
of microtubule-associated protein tau (0 of 80), TDP-43 (0 of 74), granulin (0 of 84), or 
chromosome 9 open reading frame 72 (0 of 78) were found despite testing of most patients.
Cognitive and MRI Comparisons
As a group, patients with nfvPPA had less impairment on Mini-Mental State Examination 
and Clinical Dementia Rating Sum of Boxes (Table 1). All variants showed relatively 
preserved figure copying. Patients with svPPA showed preserved working memory and 
executive functions but more behavioral impairment than both nfvPPA and lvPPA groups. 
Patients with lvPPA performed worse on the number location and calculation tests than 
patients with svPPA and nfvPPA, respectively. Both patients with lvPPA and those with 
svPPA scored worse than patients with nfvPPA on free recall of a list of learned words, but 
only patients with lvPPA scored worse on recall of the Benson figure.
Language testing revealed expected group differences based on the criteria for PPA 
subtyping (Table 1). Patients with svPPA scored significantly worse than both nfvPPA and 
lvPPA groups on tests of verbal semantic knowledge and semantic association of pictures 
using the Pyramids and Palm Trees Test. Greater presence of apraxia of speech, dysarthria, 
and decreased fluency scores differentiated patients with nfvPPA from both lvPPA and 
svPPA groups. Frank agrammatism in speech or writing was detected in 25 of 31 patients 
with nfvPPA (80.6%). Patients with lvPPA scored significantly worse than those in the 
svPPA group on sentence repetition.
Voxel-based morphometry analysis of PPA subgroups vs control groups also revealed the 
expected patterns of atrophy associated with each variant (Figure 1), bilateral predominantly 
left anterior temporal lobe in patients with svPPA, left posterior frontal lobe in patients with 
nfvPPA, and left midposterior temporal and inferior parietal lobes in patients with lvPPA.
Amyloid Imaging and Autopsy Results
Mean (SD) time between first-diagnosis PET and PET-autopsy was 244 (337) and 1641 
(926) days, respectively. Overall prevalence of amyloid PET positivity in the PPA cohort 
was 35 of 89 (39.3%). Twenty-four of 28 patients with svPPA (85.7%) and 28 of 31 patients 
with nfvPPA (90.3%) had negative amyloid PET scans, whereas 25 of 26 patients with 
lvPPA were amyloid positive (96.1%). For comparison, the rates of amyloid PET-positivity 
in patients with svPPA and nfvPPA were similar to those reported in cognitively normal 
individuals at a similar age (15%–20% in individuals aged 60–65 years32), whereas the rate 
in lvPPA was much higher than expected for age. Of the 4 patients with PPAm, 3 were 
amyloid positive and 1 was negative. Patients with lvPPA had significantly greater 11C-PiB 
SUVR than those with nfvPPA and svPPA (Figure 2 and Table 1). Although they were 
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considered to have positive results for the purposes of this study, 1 patient with svPPA and 
another with nfvPPA received “equivocally positive” amyloid PET reads. These patients 
showed evidence of focal tracer uptake in regions of early amyloid positivity (eg, precuneus/
posterior cingulate cortex, dorsomedial and dorsolateral prefrontal cortex, in contrast to the 
widespread binding patterns across large regions of association cortex that are typical in 
advanced Alzheimer disease27). Accordingly, both cases had global SUVRs consistent with 
early positivity (1.23 and 1.36, respectively) but lower than the conservative threshold used 
in our group to “rule-in” Alzheimer disease–like levels of binding (global SUVR, ≥1.40).
Autopsy diagnoses were available for 20 patients (Table 2). Overall, patients with positive 
amyloid scans all had intermediate to high Alzheimer disease neuropathological changes. 
When the PPA phenotype was lvPPA, positive amyloid PET was associated with primary 
Alzheimer disease, whereas when the PPA phenotype was nfvPPA or svPPA, the primary 
causative neuropathology was FTLD, with Alzheimer disease present as a contributing 
copathology. Conversely, all patients with negative amyloid imaging results had absent to 
low Alzheimer disease neuropathological changes, with FTLD as the primary causative 
neuropathology.
PPA With Discordant Amyloid Status
Amyloid Positive svPPA (Patients A–D)—All patients with amyloid positive svPPA 
(labeled as patients A–D) had 11C-PIB SUVRs above 2.0 except patient A, who displayed 
significant amyloid binding only in the right frontal lobe and received an “equivocally 
positive” radiologic read. Autopsy data were available for patients B and C, who received a 
mixed pathologic diagnosis: FTLD–TDP-43 type C as the primary with Alzheimer disease 
contributing. Despite having the highest 11C-PIB SUVR, patient B only showed 
intermediate Alzheimer disease neuropathological changes (Braak stage 2 and moderate 
[using the Consortium to Establish a Registry for Alzheimer Disease neuropsychological 
battery] neuritic but frequent diffuse plaques). Three of 4 (75%) had a apolipoprotein E ε4 
allele. All patients showed the typical svPPA cognitive profile and atrophy pattern (Figure 
1).
Amyloid Positive nfvPPA (Patients E–G)—Patients E, F, and G had 11C-PIB SUVRs 
above 2.0 except patient E whose scan was read as “equivocally positive” and had an SUVR 
of 1.36. Patient E had 3 contributing pathologies: FTLD-corticobasal degeneration, 
Alzheimer disease (Braak 4, Consortium to Establish a Registry for Alzheimer Disease 
neuropsychological battery frequent), and FTLD–TDP-43 type A. Patient F (previously 
described33) had a dual pathologic diagnosis: FTLD-Pick disease and Alzheimer disease 
(Braak 5, Consortium to Establish a Registry for Alzheimer Disease neuropsychological 
battery frequent). Language testing revealed varying degrees of motor speech impairment 
and agrammatism with spared verbal and visual semantics in all 3 amyloid positive nfvPPA 
cases. All cases showed atrophy in the left posterior frontal lobe with different areas of 
accompanying atrophy.
Amyloid Negative lvPPA (Patient H)—Patient H had amyloid negative lvPPA and an 
SUVR of 1.3 and autopsy data was not available. Her prominent impairment was in sentence 
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repetition but also had worse single word comprehension than the amyloid positive group. 
Voxel-based morphometry revealed a frontotemporal pattern of atrophy.
PPA Mixed
Three of 4 patients with PPAm (patients W, X, and Y) were amyloid positive and had SUVR 
greater than 2.2 (Table 1). The only patient that had an autopsy (patient Z) had FTLD-Pick 
disease. All patients showed word finding difficulties. At presentation, patients W and X 
showed impaired motor speech (apraxia of speech and dysarthria), sentence repetition, and 
grammar comprehension. Patient Y presented with impaired semantics, sentence repetition, 
and grammar comprehension. Patient Z showed impaired grammar, semantics, sentence 
repetition, and grammar comprehension. Consistent with their clinical presentation, these 
patients did not show the typical patterns of atrophy seen in the 3 main variants (Figure 3).
Discussion
We report amyloid brain imaging and cognitive and structural MRI results in the largest PPA 
cohort, to our knowledge, prospectively diagnosed using current criteria. Classification 
according to PPA variant was associated with Alzheimer disease biomarker status, with the 
logopenic variant being associated with 11C-PIB deposition in more than 95% of the patients 
with sporadic PPA. Furthermore, we found that most cases with typical svPPA and nfvPPA 
and an unexpected positive amyloid scan had mixed FTLD and Alzheimer disease 
pathology. These results suggest that typical clinical and MRI findings in svPPA and nfvPPA 
variants are associated with the presence of FTLD pathology, even in the face of discordant 
molecular Alzheimer disease biomarker results.
Association of PPA Variant Classification According to Current Consensus Criteria With 
Amyloid Imaging Biomarker Status
Four of 28 patients with svPPA (15%) and 3 of 31 patients with nfvPPA (10%) had a 
positive amyloid PET scan. These rates are similar to, if not slightly lower than, the reported 
prevalence of amyloid positivity in normal individuals at a similar age (15%–20%).32 These 
results are in line with other prospective studies, reporting amyloid positivity in 1 of 9 
patients with svPPA and 2 of 8 patients with nfvPPA,8 0 of 3 patients with svPPA and 0 of 
11 patients with nfvPPA,10 and 3 of 9 patients with svPPA and 7 of 52 patients with 
nfvPPA34 (the last study included patients labeled as having primary progressive apraxia of 
speech). Clinicopathologic studies retrospectively applying current criteria also report 
increased homogeneity of pathologic diagnoses within each PPA variant; however, the 
prevalence of an Alzheimer disease pathologic diagnosis is more heterogenous, particularly 
in lvPPA and nfvPPA (0%–16% svPPA, 13%–31% nfvPPA, and 54%–77% lvPPA).5–7,35 
Although well-studied cases of nfvPPA and svPPA with Alzheimer disease pathology have 
been reported,36,37 it is possible that the higher percentage of Alzheimer disease in these 
studies is due in part to the difficulty of retrospectively assessing key diagnostic features 
such as apraxia of speech, agrammatism, repetition, and semantic impairment. Even today, 
these key features are evaluated with different instruments across centers and represent a 
significant hurdle for comparison and generalization of results. Furthermore, all of the 
amyloid discordant cases with available autopsy data (two svPPA and two nfvPPA) in our 
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study had primary FTLD and secondary Alzheimer’s disease pathological diagnoses 
suggesting that a substantial proportion of amyloid positive svPPA and nfvPPA patients may 
have a primary FTLD pathologic diagnosis with amyloid as a contributing or incidental 
pathology.
Our finding of only 1 amyloid negative out of 26 patients with lvPPA (96% amyloid 
positive) is also in line with the rates of amyloid positivity (80%–100%) reported in other 
prospective PPA cohort studies.8,10,11 Despite the general association of lvPPA with 
Alzheimer disease, this study and others have reported cases of patients prospectively8,11–13 
and retrospectively diagnosed as having lvPPA5–7,14 without Alzheimer disease biomarkers 
or pathology. The studies reporting retrospective diagnoses all report higher rates of non-
Alzheimer disease pathology in lvPPA than the ones reporting prospective diagnoses 
possibly due to the absence of targeted neuropsychological evaluations that have been 
implemented more recently. The reasons for discrepancies in the rates of amyloid-negative 
lvPPA are unknown but probably reflect real differences in patient cohorts (such as absence 
of mutation carriers in our cohort) as well as variability in the application of diagnostic 
criteria across centers.
PPA With Discordant Amyloid Status
We did not find any demographic, genetic, cognitive, or neuroimaging features that reliably 
distinguished amyloid positive svPPA or nfvPPA from their primarily amyloid-negative 
counterparts. Carrying an apolipoprotein E ε4 allele was a risk factor for amyloid positivity 
even within just svPPA and nfvPPA (odds ratio, 5.6; 95% CI, 1.1–29.1; P = .04). No genetic 
mutations were found in any of these cases. All 4 amyloid-positive patients with svPPA 
showed the same language and atrophy profiles as the amyloid-typical group concordant 
with the available autopsy data and suggest FTLD may be the primary pathologic diagnosis 
in all 4 patients. Two patients showed highly impaired set shifting in the Modified Trail 
Making Test, which is unusual for typical svPPA and may reflect an Alzheimer disease 
contribution to the clinical picture.38 All amyloid-positive patients with nfvPPA also showed 
the typical language profile and a common area of atrophy in the left posterior frontal lobe, 
although each case presented different areas of accompanying atrophy perhaps reflecting the 
heterogeneous pathologic diagnoses that are known to be associated with nfvPPA. The 
amyloid negative lvPPA case in our cohort showed more semantic impairment, and her 
pattern of left temporal atrophy was more anterior and left asymmetric than the amyloid 
positive lvPPA group. Recent studies have also reported a trend toward worse semantics13 
and greater left asymmetric anterior temporal atrophy and/or hypometabolism11,12 in 
amyloid-negative lvPPA. According to current genetic and pathologic data, most amyloid 
negative lvPPA cases are associated with an autosomal dominant granulin mutation11,39 or 
sporadic TDP-43–A pathology.5–7
Diagnosis According to Current PPA Consensus Criteria Classified the Majority of Patients 
Who Met Root PPA Criteria
Similar to other recent studies,6–8 we identified the initial predominantly impaired language 
domain and classify almost all (85 of 89 [95.5%]) patients that met root PPA criteria. 
However, some studies report inability to classify a higher proportion of patients, especially 
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when attempting data-driven vs clinical classification methods.40,41 The 2 main issues 
described in previous reports are that a significant number of patients present with both 
agrammatism and sentence repetition impairment, thus meeting criteria for both nfvPPA and 
lvPPA, while other patients present only with anomia and thus do not meet any criteria.5,34 
Despite the existence of unclear cases that required discussion, in our experience and that of 
others, application of current criteria and targeted speech and language assessments using 
clinical judgment to identify the predominantly impaired and relatively spared language 
domains can resolve many of these cases. Furthermore, visual inspection of MRI scans were 
always used when available to make an imaging-supported diagnosis as defined in the 
consensus criteria.2 It is also important to note that the low number of mixed cases in our 
cohort might be related to the absence of progranulin mutation carriers, who have been 
shown to present with a logopenic-like mixed PPA syndrome.39 A possible factor in the 
absence of patients presenting only anomia in our cohort could be that the aphasia tended to 
be further evolved before referral to our specialty center.
All 4 patients with PPAm in our cohort presented a mix of core features and atrophy typical 
of more than 1 variant, which were thought to contribute significantly to the clinical picture. 
Even before knowing the result of the amyloid imaging, Alzheimer disease was the 
predicted pathology in both patients with mixed phonological and motor speech impairment 
due to the relative predominance of phonologic impairment, posterior vs frontal atrophy, and 
presence of impaired memory neuropsychological scores. No patients presented with 
another previously described PPAm phenotype of equally impaired grammatical production 
and verbal semantics.42 Further studies including larger numbers of mixed cases are needed 
to determine if these present with consistent clinical-pathologic associations.
Limitations
The main limitations of this study stem from the sample size and possible referral bias. 
Primary progressive aphasia is a rare disorder, and despite the relatively large size and 
extensive characterization (clinical, cognitive, and multimodal neuroimaging) of our cohort, 
the sample size is too small to establish firm conclusions. In particular, our findings with 
respect to the amyloid discordant and mixed PPA cases warrant further study. Another issue 
that could limit generalization of our results is referral bias. For example, a possible factor in 
the absence of patients presenting only anomia in our cohort could be that the aphasia tended 
to be further evolved prior to referral to our specialty center. Referral bias could also be a 
factor in the small numbers of mixed cases and patients with genetic mutations in our cohort 
compared to other centers that report a higher proportion of patients with these 
characteristics.
Conclusions
Primary progressive aphasia variant imaging-confirmed diagnosis according to 2011 
consensus classification was associated with Alzheimer disease biomarker status. 
Furthermore, our results emphasize that positive amyloid biomarker status does not rule out 
the possibility of a primary FTLD pathologic process driving the clinical syndrome.
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What are the rates and significance of amyloid imaging positivity in a large cohort of 
patients with the main variants of primary progressive aphasia (PPA) prospectively 
diagnosed according to 2011 consensus criteria?
Findings
In this longitudinal case-series study, 24 of 28 patients with semantic variant PPA (86%) 
and 28 of 31 patients with nonfluent/agrammatic variant PPA (90%) had negative 
amyloid positron emission tomography scans, whereas 25 of 26 patients with logopenic 
variant (96%) and 3 of 4 patients with PPA with mixed phenotype (75%) had positive 
scans. The amyloid positive semantic PPA and nonfluent/agrammatic PPA cases with 
available autopsy data (2 of 4 and 2 of 3, respectively) all had a primary frontotemporal 
lobar degeneration and secondary Alzheimer disease pathologic diagnoses.
Meaning
Primary progressive aphasia variant diagnosis according to the current classification 
scheme is highly predictive of Alzheimer disease biomarker status; biomarker positivity 
for Alzheimer disease may be more predictive of mixed pathology rather than primary 
Alzheimer disease.
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Figure 1. Single-Participant Voxel-Based Morphometry of Amyloid Discordant Patients
A, The first row corresponds with the pattern of atrophy in the semantic PPA (svPPA) 
amyloid negative group (n = 24), and the subsequent rows correspond with amyloid 
discordant svPPA in patients A, B, C, and D. B, The first row corresponds with the pattern of 
atrophy in the amyloid negative nonfluent/agrammatic PPA (nfvPPA) group (n = 28), and the 
subsequent rows correspond with amyloid discordant nfvPPA in patients E, F, and G. C, The 
first row corresponds with the pattern of atrophy in the logopenic PPA (lvPPA) amyloid 
positive group (n = 25), and the subsequent row corresponds with amyloid discordant lvPPA 
patient H. PPA indicates primary progressive aphasia. L indicates left; R, right.
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Figure 2. Amyloid Positron Emission Tomography in the 3 Main PPA Variants
Scatterplot depicting positron emission tomography carbon 11–labeled Pittsburgh 
Compound-B (11C-PIB) standardized uptake value ratios (SUVR) across primary 
progressive aphasia (PPA) variants (A). 11C-PIB axial slices of a representative patient with 
semantic PPA (svPPA) (B), nonfluent/agrammatic PPA (nfvPPA) (C), and logopenic PPA 
(lvPPA) (D). L indicates left; R, right.
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Figure 3. Voxel-Based Morphometry of Gray Matter Atrophy Patterns
Voxel-based morphometry of gray matter atrophy patterns for amyloid positive primary 
progressive aphasia (PPA) mixed (PPAm) in patientW, X, and Y (A), and amyloid negative 
PPAm in patient Z (B). L indicates left; R, right.
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